Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies.
暂无分享,去创建一个
[1] R G Ulrich,et al. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. , 2001, Toxicology letters.
[2] J R Yates,et al. Mass spectrometry. From genomics to proteomics. , 2000, Trends in genetics : TIG.
[3] J. Yates,et al. Large-scale analysis of the yeast proteome by multidimensional protein identification technology , 2001, Nature Biotechnology.
[4] J. Trent,et al. Microarrays and toxicology: The advent of toxicogenomics , 1999, Molecular carcinogenesis.
[5] Katsushi Tokunaga,et al. The power of genome-wide association studies of complex disease genes: statistical limitations of indirect approaches using SNP markers , 2001, Journal of Human Genetics.
[6] F. Gilbert. Disease genes and chromosomes: disease maps of the human genome. , 2000, Genetic testing.
[7] George M. Church,et al. Regulatory Networks Revealed by Transcriptional Profiling of Damaged Saccharomyces cerevisiae Cells: Rpn4 Links Base Excision Repair with Proteasomes , 2000, Molecular and Cellular Biology.
[8] Jørgen K. Kanters,et al. Screening for mutations and polymorphisms in the genes KCNH2 and KCNE2 encoding the cardiac HERG/MiRP1 ion channel: implications for acquired and congenital long Q-T syndrome. , 2001, Clinical chemistry.
[9] N. Anderson,et al. Simultaneous Measurement of Hundreds of Liver Proteins: Application in Assessment of Liver Function , 1996, Toxicologic pathology.
[10] W. Weber. Effect of pharmacogenetics on medicine , 2001, Environmental and molecular mutagenesis.
[11] S. Gottesman,et al. Posttranslational quality control: folding, refolding, and degrading proteins. , 1999, Science.
[12] R. Dunn,et al. Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.
[13] W. Kalow. Contribution of hereditary factors to the response to drugs. , 1965, Federation proceedings.
[14] W. Kalow. PHARMACOGENETICS IN ANIMALS AND MAN , 1968 .
[15] D. Nebert. Drug-Metabolizing Enzymes, Polymorphisms and Interindividual Response to Environmental Toxicants , 2000, Clinical chemistry and laboratory medicine.
[16] E Holmes,et al. Metabonomic characterization of genetic variations in toxicological and metabolic responses using probabilistic neural networks. , 2001, Chemical research in toxicology.
[17] J. T. Macgregor,et al. Strategies and testing methods for identifying mutagenic risks. , 2000, Mutation research.
[18] W. Weber,et al. Populations and genetic polymorphisms. , 1999, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.
[19] E. Sim,et al. Arylamine N-acetyltransferases - of mice, men and microorganisms. , 2001, Trends in pharmacological sciences.
[20] F. Kadlubar. Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans. , 1994, Drug metabolism reviews.
[21] R. Dunn,et al. Concise review: gene expression applied to toxicology. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.
[22] T. Lindahl,et al. Quality control by DNA repair. , 1999, Science.
[23] P. de Knijff,et al. A powerful and rapid approach to human genome scanning using small quantities of genomic DNA. , 2001, Genetical research.
[24] S. Cohen,et al. The manipulation of genes. , 1975, Scientific American.
[25] Toward construction of a transcript profile database predictive of chemical toxicity. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.
[26] T. Ørntoft,et al. Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics , 2000, FEBS letters.
[27] Maclyn McCarty,et al. STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES , 1944, The Journal of experimental medicine.
[28] William Epstein,et al. Nuclear-Free Zones , 1975 .
[29] S. Schreiber,et al. Printing proteins as microarrays for high-throughput function determination. , 2000, Science.
[30] W. Kalow. Part I. Drug Metabolism Enzymes , 1968 .
[31] Maclyn,et al. CELEBRATING THE THIRTY-FIFTH ANNIVERSARY OF THE PUBLICATION ' OF " STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES " Induction of Transformation by a Desoxyribonucleic Acid Fraction Isolated From Pneumococcus Type III , 1998 .
[32] E Holmes,et al. Chemometric models for toxicity classification based on NMR spectra of biofluids. , 2000, Chemical research in toxicology.
[33] J. Lindon,et al. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[34] R. Tennant,et al. Transgenic animals in toxicology. , 1994, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[35] Steven J Smith,et al. Cardiovascular Toxicity of Antihistamines , 1994, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[36] L J Lesko,et al. Pharmacogenomic-guided drug development: regulatory perspective , 2002, The Pharmacogenomics Journal.
[37] J. Yates. Mass spectrometry and the age of the proteome. , 1998, Journal of mass spectrometry : JMS.
[38] A Helenius,et al. Setting the standards: quality control in the secretory pathway. , 1999, Science.
[39] F. Taddei,et al. Counteraction by MutT protein of transcriptional errors caused by oxidative damage. , 1997, Science.
[40] J. Llenas,et al. Some observations on the cardiotoxic and drug interaction profiles of second generation antihistamines as measured in the guinea pig. , 1996, Arzneimittel-Forschung.
[41] A. Ronen,et al. Human DNA repair genes , 2001, Environmental and molecular mutagenesis.
[42] F. A. Denz,et al. Experimental methods used in determining chronic toxicity; a critical review. , 1954, Pharmacological reviews.
[43] L. Samson,et al. Global response of Saccharomyces cerevisiae to an alkylating agent. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[44] W. Pennie. Use of cDNA microarrays to probe and understand the toxicological consequences of altered gene expression. , 2000, Toxicology letters.
[45] T. Nyström,et al. Protein oxidation in response to increased transcriptional or translational errors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[46] R. Egan,et al. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. , 1996, Arzneimittel-Forschung.
[47] Timothy B. Stockwell,et al. The Sequence of the Human Genome , 2001, Science.
[48] B. W. Penman,et al. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. , 1997, Advances in pharmacology.
[49] F. Crick,et al. Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid , 1953, Nature.
[50] J. Speyer,et al. Synthetic polynucleotides and the amino acid code. , 1961, Proceedings of the National Academy of Sciences of the United States of America.
[51] M Pirmohamed,et al. Genetic susceptibility to adverse drug reactions. , 2001, Trends in pharmacological sciences.
[52] R. Langenbach,et al. Human cell lines, derived from AHH-1 TK+/- human lymphoblasts, genetically engineered for expression of cytochromes P450. , 1993, Toxicology.
[53] F. Kadlubar,et al. Metabolic polymorphisms and carcinogen-DNA adduct formation in human populations. , 1995, Pharmacogenetics.
[54] D J Dix,et al. Application of DNA arrays to toxicology. , 1999, Environmental health perspectives.
[55] J. Lederberg,et al. `Ome Sweet `Omics--A Genealogical Treasury of Words , 2001 .